Get started
Author

Francisco Adrian

Observed name: F. Adrian
OpenAlex ID: A5035503744
Phase I study of HFB200301, a first-in-class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS).
2022 · Alexander I. Spira, Aung Naing, et al. · Journal of Clinical Oncology · 7
783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)
2022 · A. Spira, R. Mehra, et al. · Annals of Oncology · 5
PDF
HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering
2026 · Jiliang Zhao, Dongping Zhang, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract 6202: Integrating public single-cell transcriptomics and patient profiles to guide clinical development
2024 · Jack Russella-Pollard, Joshua Whitener, et al. · Cancer Research · 1
Abstract 3477: Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer immunotherapy
2023 · Tom Li Stephen, Qian Zhang, et al. · Cancer Research · 1
Abstract 4248: HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
2022 · Juying Li, Qian Zhang, et al. · Cancer Research · 1
Abstract 618: Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
2022 · Dean Lee, Monika Manne, et al. · Cancer Research · 1
Abstract 2899: Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
2022 · Roshan M. Kumar, Julie Prigent, et al. · Cancer Research · 1
994P Potential predictive biomarkers of clinical benefit from Emunkitug (HFB200301) in combination with tislelizumab: Integrated analysis of tumor, peripheral blood, and patient treatment history
2025 · D. Roda Perez, A. Chung, et al. · Annals of Oncology
949P Evaluation of HVEM and PD-L1 expression profile in tumors as potential predictive biomarkers for HFB200603, a BTLA antagonist, as monotherapy and in combination with tislelizumab
2025 · M.J. De Miguel, E. Márquez, et al. · Annals of Oncology
CXCR5 as a Therapeutic Target in Autoimmune Diseases: Insights from Sjögren’s Syndrome
2025 · Germain Margall Ducos, Sophie Foulon, et al. · Journal of Human Immunity
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
2024 · D. Roda Perez, J. Zugazagoitia, et al. · Annals of Oncology
Abstract 7176: Optimization of T cell co-stimulatory agonists: A semi-mechanistic PKPD model integrating drug properties and tumor-immune interactions
2024 · Jinping Gan, William Hedrich, et al. · Cancer Research
Works count: 13
Citation count: 17
H-index: 2
I10-index:
Year
Topic
Type